Bladder cancer
Keytruda shows promise in bladder cancer trial, Merck says
Merck’s immunotherapy drug, Keytruda, continues to demonstrate success in the field of bladder cancer. After securing FDA approvals for use ...
ImmunityBio cuts 50 jobs in California and Florida after FDA snubs its bladder cancer drug
Following an FDA rejection earlier this year, ImmunityBio has initiated its second round of layoffs in less than a year, ...
Padcev-Keytruda combo cuts death risk in first-line bladder cancer
As Seagen readies itself for its impending acquisition by Pfizer, a significant triumph emerges for the company’s cancer drug Padcev, ...
Ferring launches bladder cancer gene therapy Adstiladrin in US through early experience program
Ferring Pharmaceuticals achieved a significant milestone by administering its groundbreaking gene therapy, Adstiladrin, to its first commercial patient. This innovative ...
Tecentriq SC: A Swift Leap Forward in Cancer Treatment Receives Green Light
Roche has proudly unveiled that Tecentriq SC (atezolizumab) has received the stamp of approval from the Medicines and Healthcare products ...
Ferring Strikes $500M Agreement with Royalty Pharma for Innovative Bladder Cancer Gene Therapy
Royalty Pharma has carved a distinctive niche in the pharmaceutical landscape, specializing in identifying innovative products both pre- and post-approval, ...
